Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Two B gearing up for next step against Parkinson's with fixed-dose drug

This article was originally published in Scrip

Executive Summary

Fresh off its positive Phase I results reported last month, Israeli drug maker Pharma Two B said it is gearing up to start a Phase II study of its experimental fixed-dose combination therapy P2B001, which is being tested as a treatment for early-stage Parkinson's disease (scripintelligence, 14 April 2011).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts